Daily price updates
What planify offer?
Join our channel partner program
Content
Get detailed information about the Hicks
Thermometers Pre IPO shares. In this research report, you will get to know
about Hicks Thermometers India
Limited Key Ratio data. In addition, get the Complete details about
the Net Profit Growth, Revenue Growth and Book Value Growth.
Growth in %
17.63%
1 Year
9.39%
3 Year
7.38%
6 Year
The revenue for the company grew from Rs. 58.86 cr in FY20 to Rs. 69.24 cr. in FY21, showcasing a growth of 18% year on year (y-o-y). The revenue from sales of goods grew at a rate of 18% y-o-y, which is primarily attributable to a surge in demand for home and personal care products like thermometers, hand sanitizers, face masks, and Disinfection solutions due to covid 19 1st wave.
Growth in %
70.57%
1 Year
52.84%
3 Year
21.65%
6 Year
The company's net income has increased by 71% in FY21 to Rs. 5.49 cr. from Rs. 3.22 cr. in FY20. The firm's revenue per-unit expense for FY21 stands at 1.077, which is higher than FY20, which was 1.049. The reason for this growth was both an increase in the topline of the company as well as efficient cost management in comparison to the growth in revenue. The overall expense of the company grew to Rs 63.75 cr. in FY21 from Rs. 55.64 cr. in FY20, increasing by around 15% y-o-y.
Growth in %
70.57%
1 Year
52.84%
3 Year
21.65%
6 Year
The company's EPS grew at a rate of 71% in 2021 compared to 2020, driven by a 71% y-o-y growth in net income from Rs.3.22 cr in FY20 to Rs. 5.49 cr. in FY21. The total outstanding shares for the company remain the same for the year at 2,79,540.
Growth in %
28.05%
1 Year
20.89%
3 Year
32.43%
6 Year
The company's book value has increased at a growth rate of 28%, primarily because of increased reserves and surplus by 33% in FY21 compared to FY20 this was driven due to increased retained earnings for FY21. Whereas the capital reserve and the general reserve for the company remain same for the year. The total number of shares outstanding remained the same at 2,79,540.
Growth in %
58.66%
1 Year
39.22%
3 Year
18.66%
6 Year
EBITDA grew at a rate of 59%, from Rs 5.04 cr. in FY20 to Rs. 7.99 cr. in FY21. The reason for this growth in EBITDA was strong revenue growth y-o-y by 18%. The overall operating expense grew by 14% y-o-y, where the rise was contributed by the purchase of stock in trade by Rs. 7.58 cr. , a hike in the salaries and wages by Rs. 1.08 cr. The other operating expense also saw a rise of 16% y-o-y due to an increased cost of advertisement, postal, telephone, and repair & maintenance.
Growth in %
63.45%
1 Year
42.77%
3 Year
19.56%
6 Year
The EBIT rose to Rs. 7.73 cr. in FY21 from Rs. 4.73 cr. in FY20, showcasing an increase of 63%. An increase in operating margin is due to an overall increase in the EBITDA of the company which rose by 59% y-o-y also the depreciation and amortization expense of the company has decreased a bit from Rs. 0.31 cr. in FY20 to Rs. 0.26 cr. in F21, which is a decrease of 15% y-o-y.
Growth in %
30.05%
1 Year
12.09%
3 Year
11.31%
6 Year
Total assets have increased from Rs. 25.68 cr. to Rs. 33.23 cr. This is primarily due to an increased inventory, trade receivables, and cash & cash equivalents by Rs 5.44 cr., Rs. 0.71 cr., and Rs. 1.37 cr. respectively. This significant increase in inventory is because the company wanted sufficient stock to cater to the high demand for personal medical care due to covid -19.
Growth in %
-45.86%
1 Year
59.99%
2 Year
28.76%
5 Year
Cash flow from operations showed a fall. It was Rs. 5.32 cr. in FY20 and fell to Rs. 2.88 cr. in FY21. The fall primarily accounts for the addition of inventory by the company in FY21.
The overall D/E ratio of the company has seen a fall of 28% but the long-term borrowing of the company has shown an increase of Rs 0.59 cr. in FY21, and the short borrowing has shown an increase from Rs. 0.44 cr. in FY21. The reason for the fall in the D/E ratio even when the overall debt has increased by Rs. 1.03 cr. is the rise in other equity of the company as the company's reserves and surplus rose by Rs. 5.49 cr. in FY21 which increased the overall total equity by 32% y-o-y, which led to a fall in D/E ratio of the company.
The company's current ratio has increased from 4.2 to 4.6, a rise of 13% in FY21 over FY20. The change in cash & other short-term investments from Rs. 8.87 cr. in FY20 to Rs 10.25 cr. in FY21, as well as the receivables and inventory, also rose by 13% and 65% respectively. The other current liabilities rose a bit due to an increased short-term dent and accounts payable by Rs 0.44 cr. and Rs 0.97 cr. respectively.
The company's interest coverage ratio has increased by 111.9 % from last year due to an increase in the EBIT of the company by 63% year on year due to the rise in revenue due to high demand for personal healthcare products in FY21. Also, the interest expense has also decreased by 23% y-o-y, all of this led to significant increase in interest coverage ratio of the firm.
The company's operating efficiency has shown a significant increase in FY21 when compared to FY20 reason being EBIT and PBT margins both have seen a rise of 39% and 47% in FY21 y-o-y. The reason to drive this growth is 11% revenue growth in FY21 due to a drastic increase in demand for medical equipment like Thermometer, Monitoring devices, sanitizers, and face masks reason being COVID-19.
ROE of the company in FY21 has witnessed a growth of 33% in FY21 from FY20. As per Dupont Analysis, the net income margin drove an overall increase in the ROE. Net income margin has witnessed a growth of 45% in FY21 from FY20, the reason being the increase in revenue because as being the market leader it enjoyed the health demand generated due to covid -19. Overall, the asset turnover ratio has seen a decline of 4% in FY21 from FY20, as the company has increased its assets which shows that the company is focused on its growth.
The return on capital employed of the company has shown a rise of 31% from 25% in FY20 to 33% in FY21. This is because the company's capital has increased by 30% in FY21 over FY20 due to the increased debt and other equity. On the other hand, the EBIT of the company increased by 63% in FY21 over FY20. As a result, the ROCE rose to 33% in FY21.
ROA of Hicks thermometers has seen a 40% rise y-o-y. The reason for this rise is the CAPEX investment by the company is 2021, which the company has done by adding on more inventory and long-term investments. The company's net income has seen an increase of 71% in FY21 compared to FY20.
